Pharmacovigilance: The Subsequent Section

Pathan Musab Haji Farukh[1], Mirza Sharjil Beg Raees Beg[2], Shaikh Zeeshan Shaikh Sajid[3]
Dr. Taarique Deshmukh[4], Dr. Rashid Akhtar Nehal Ahmad[5]

Students, Royal College of Pharmaceutical Education and Research, Malegaon, Maharashtra, India[1,2,3]
Teacher, Royal College of Pharmaceutical Education and Research, Malegaon, Maharashtra, India[4]
Principal, Royal College of Pharmaceutical Education and Research, Malegaon, Maharashtra, India[5]

Abstract*: Analyzing spontaneously reported cases with great care has long been the foundation for the identification and measurement of adverse drug reactions. An essential component of the analysis of individual case reports was the assessment of causality (imputation). Analysis of aggregated cases and disproportionality analyses in databases of spontaneous reports were added to this. These have changed drug information by leading to the discovery of numerous new adverse reactions in the lack of more focused information sources. Many drugs have been pulled off the market as a result of it, but its application to risk quantification is still unclear. The generation of hypotheses for serious adverse drug reactions, particularly those that lead to hospital admission or death, is largely dependent on spontaneous reporting, as evidenced by the accessibility of databases holding electronic health records or claims data for the entire population. In these situations, the events can be precisely quantified using the instruments of contemporary pharmacoepidemiology to produce benefit-risk analyses that are specific to the population. Despite its inherent limitations, spontaneous reporting is still essential for generating signals and alerts related to drug safety. Further systematic and quantitative methods, like claims databases for reactions resulting in hospital admissions, should be pursued for signal strengthening and assessment*

Keywords: Drug safety, population databases, pharmacovigilance, and pharmacoepidemiology